CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) Short Interest Down 97.9% in December

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) was the recipient of a significant decrease in short interest in the month of December. As of December 31st, there was short interest totalling 150,000 shares, a decrease of 97.9% from the December 15th total of 7,300,000 shares. Based on an average trading volume of 906,000 shares, the short-interest ratio is presently 0.2 days. Approximately 16.5% of the shares of the stock are short sold.

CERo Therapeutics Trading Down 17.3 %

Shares of CERO stock traded down $0.57 during trading hours on Tuesday, hitting $2.72. The stock had a trading volume of 229,504 shares, compared to its average volume of 1,700,875. The stock’s 50-day moving average price is $11.81 and its two-hundred day moving average price is $13.07. CERo Therapeutics has a one year low of $2.67 and a one year high of $1,280.00.

Insider Transactions at CERo Therapeutics

In other CERo Therapeutics news, major shareholder Bioventures Opportunities G. Yk sold 8,505 shares of the business’s stock in a transaction on Monday, December 9th. The shares were sold at an average price of $11.00, for a total value of $93,555.00. Following the sale, the insider now owns 205,333 shares in the company, valued at $2,258,663. The trade was a 3.98 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold a total of 64,300 shares of company stock valued at $529,409 over the last 90 days. Company insiders own 18.00% of the company’s stock.

CERo Therapeutics Company Profile

CERo Therapeutics Holdings, Inc, an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.